Cellectis S.A. · EURONEXT:ALCLS

Cellectis — Investor Presentation (September 2019)

32 slides from Cellectis's investor presentation, Sep 10, 2019

  1. Slide 1: Commitment to a Cure

    COMMITMENT TO A CURE cellectis.com

  2. Slide 2: Forward-Looking Statements

    FORWARD-LOOKING STATEMENTS This presentation contains “forward-looking” the risk that any one or more of our product statements that are based on our management’s candidates will not be successfully developed current expectations and assumptions and on and commercialized. information currently avail

  3. Slide 3: Our Mission

    OUR MISSION Leverage our leadership in gene editing and CAR-T therapy to bring new hope to cancer patients through broadly available, off-the-shelf therapies P3

  4. Slide 4: Cellectis - Commitment to a Cure

    CELLECTIS - COMMITMENT TO A CURE * INNOVATION LEADERSHIP PIPELINE MANUFACTURING Protein engineering for First clinical proof-of-concept for Pioneering robust Scalable, efficient process best-in-class gene editing allogeneic CAR-T therapies, first first-in-class allogeneic to generate consistent and

  5. Slide 5: Advantages of Allogeneic vs. Autologous CAR-T

    ADVANTAGES OF ALLOGENEIC VS. AUTOLOGOUS CAR-T Allogeneic process: consistent manufacturing + quality immediate treatment assurance HEALTHY DONOR SCALABLE MASS PRODUCED 1. CANCER 2. OFF-THE-SHELF APHERESIS MANUFACTURING OFF-THE-SHELF TREATMENT CAR-T THERAPY OF 100+ DOSES/BATCH CAR-T THERAPIES DECISIO

  6. Slide 6: TALEN: Best-in-Class Gene Editing

    TALEN®: BEST-IN-CLASS GENE EDITING PRECISION SPECIFICITY EFFICIENCY targeting within 6 base pairs of recognition site is 32 TCR-α can be knocked-out with over any target in the genome base pairs long 95% efficacy for engineered CAR T- (effective changes) (avoids errors) cells (ensures yield) Editing

  7. Slide 7: UCARTs – Allogeneic CAR T-Cells Through Precision Gene Editing

    UCARTs – ALLOGENEIC CAR T-CELLS THROUGH PRECISION GENE EDITING RATIONAL EFFECTIVE Engineering Persistence via accurate insertion via knock-out of CD52 or of best CAR β2-microglobulin UCART Universal Chimeric Antigen Receptor T-cell TUMOR CELL SAFE SMART Administration Action Avoid GvHD via knock-out

  8. Slide 8: Partnerships with Industry Leaders

    PARTNERSHIPS WITH INDUSTRY LEADERS Development & commercialization partners Equity investor UCART19 (with Allogene) 15 LICENSED TARGETS 6.57% of outstanding + other targets shares Up to $1.1B in development Up to $2.8B in development milestones & sales milestones As of April 30, 2019 Royalties on sa

  9. Slide 9: Pipeline: Innovative Cancer Therapies for Unmet Needs

    PIPELINE: INNOVATIVE CANCER THERAPIES FOR UNMET NEEDS Program Indication Target Pre-clinical Phase 1 Phase 2 / 3 2019 Anticipated Milestones UCART19* ALL CD19 Mar. 2016 C TA Mar. 2017 UCART123 AML CD123 Feb. 2017 UCART22 ALL CD22 Jun. 2018 First dosing expected ALLO-501* NHL CD19 Jan. 2019 UCARTCS1

  10. Slide 10: Pipeline Targets Multiple Unmet Needs in Cancer

    PIPELINE TARGETS MULTIPLE UNMET NEEDS IN CANCER ALL AML MM UCART22 UCART123 UCARTCLL1 UCARTCS1 Incidence rates per year 48,297 30,000 30,770 19,520 5,960 7,500 U.S. E.U. U.S. E.U. U.S. E.U. Survival data 20% 27% 50% 5 years OS* in adults 5 years OS in adults 5 years OS in adults <6 months median 6%

  11. Slide 11: UCART19: Design of Phase 1 Studies in R/R ALL

    UCART19*: DESIGN OF PHASE 1 STUDIES IN R/R** ALL*** CD19 is a validated target expressed in B-cell malignancies Adult ALL (CALM study) PRIMARY OBJECTIVE SECONDARY OBJECTIVES Evaluate safety, tolerability, Objective remission rate at Day maximum tolerated dose 28. Duration of response, time to ONGOIN

  12. Slide 12: UCART19: Phase 1 R/R ALL Data Presented at ASH 2018

    UCART19*: PHASE 1 R/R ALL – DATA** PRESENTED AT ASH 2018 Safety: Efficacy: N=21 82% CR/CRi rate in FCA***-treated patients 67% overall CR/CRi rate CALM PALL 71% of these patients were MRD- 14% Grade 3-4 Cytokine Release Syndrome Redosing with UCART19 resulted in cell expansion and MRD- status in 2/3 p

  13. Slide 13: CD123 Target: Rationale for Therapy

    CD123 TARGET: RATIONALE FOR THERAPY Incidence rates per year High expression on malignant Limited expression on healthy cells cells AML HL CD123 30,000 CD123 is expressed 19,520 over 90% on malignant 17,000 cells in AML, and also CD123 8,110 expressed on BPDCN and Hodgkin’s lymphoma U.S. E.U. U.S. E

  14. Slide 14: UCART123 – Phase 1 Study in AML

    UCART123 – PHASE 1 STUDY IN AML Patient characteristics Age and fitness: R/R in AML Mutation status: Progression: rapid 65 years and older, unfit patients genetically complex progression following relapse Dose escalation (mTPI*) phase (R/R AML) 28 days between the first 2 patients for each dose**, t

  15. Slide 15: UCART123 – Preclinical Rationale in AML

    UCART123 – PRECLINICAL RATIONALE IN AML Development rationale: High expression: blasts, Unmet need: high relapse rate and Validated target: CD123 - clinically independent of mutation status poor survival in R/R patients validated in autologous CAR T-cell trials Elimination of AML cells Dose-dependen

  16. Slide 16: CD22 Target: Rationale for Therapy

    CD22 TARGET: RATIONALE FOR THERAPY Incidence rates per year Expression on malignant cells Potential in disease space ALL NHL CD22 Relapses following a 115,118 CAR T-cell therapy, with malignant cells expressing 74,680 CD22 is expressed CD22 on B-cell malignancies B-ALL patients 7,500 expressing CD22

  17. Slide 17: UCART22 – Phase 1 Trial Design in ALL

    UCART22 – PHASE 1 TRIAL DESIGN IN ALL Patient characteristics Age and fitness: CD19- & CD19+ ALL Offers a therapeutic solution to patients who cannot receive, or R/R B-ALL < 65 years high CD22 expressing B-malignant cells relapsed, after autologous CD19 CAR T-cell therapy Dose escalation (mTPI) phas

  18. Slide 18: UCART22 – Preclinical Rationale for ALL

    UCART22 – PRECLINICAL RATIONALE FOR ALL Development rationale: CD22 expression: in CD19 Unmet need: high relapse rates (CD19-) after Validated target Expandable market: potential CD19 negative blasts CAR-T treatment, poor survival in R/R patients in ALL and NHL expansion into first-line ALL Control

  19. Slide 19: CS1-SLAMF7 Target: Rationale for Therapy

    CS1-SLAMF7 TARGET: RATIONALE FOR THERAPY High expression Limited expression Monoclonal antibody Incidence rates per year on malignant cells on healthy cells validation MM CS1 CS1 Elotuzumab is a monoclonal antibody targeting CS1 48,297 CS1 expression Elotuzumab is safe and effective (also known as i

  20. Slide 20: UCARTCS1 – Phase 1 Trial Design in Multiple Myeloma

    UCARTCS1 – PHASE 1 TRIAL DESIGN IN MULTIPLE MYELOMA Patient characteristics Age and fitness: R/R MM patients < 65 years Dose escalation (mTPI*) phase 28 days between first 2 patients, then 14 days between each consecutive patient R/R MM To start at MD Up to 18 patients Anderson DL1 DL2 DL3 Expansion

  21. Slide 21: UCARTCS1 – Preclinical Rationale in Multiple Myeloma

    UCARTCS1 – PRECLINICAL RATIONALE IN MULTIPLE MYELOMA Dose-dependent enhanced survival Knock-Out of CS1 on CAR T-cells to suppress cross T-cell reaction between UCARTCS1 UCARTCS1 UCARTCS1 CAR % survival CS1 CS1 Antigen Tumor cell T-Cell time (days) Day -10: tumor cells injection Day 0: treatment Prec

  22. Slide 22: Building the Future of Allogeneic CAR T-Cell Therapy

    BUILDING THE FUTURE OF ALLOGENEIC CAR T–CELL THERAPY 2019 objectives: 3 proprietary programs in the clinic; 3 partnered programs in the clinic UCART123 UCART22 UCARTCS1 UCARTCLL1 Phase 1 for R/R AML Phase 1 dosing in R/R and Phase 1 dosing in R/R MM Preclinical for R/R AML naive ALL in 2019 Potentia

  23. Slide 23: TALEN Gene Editing – Advantages

    TALEN® GENE EDITING – ADVANTAGES TALEN®: Driven by protein/DNA Releases DNA ends accessible to DNA repair Over 25 years of building a strong interactions to work on potential mechanisms to perform gene insertions and corrections patent portfolio with umbrella off-site cleavage through homologous rec

  24. Slide 24: Optimizing Yield Through Highest Gene Editing Efficiency

    OPTIMIZING YIELD THROUGH HIGHEST GENE EDITING EFFICIENCY High Knock-Out and Knock-In efficiency and specificity TCRab TCRab CAR 95.2% single targeted gene Knock-Out ~80% single gene integration TRAC Knock-Out CAR Knock-In at TRAC Locus High Specificity High specificity Prevents GvHD Enables efficiency

  25. Slide 25: Power of TALEN Gene Editing: Multiplexing Gene Replacement

    POWER OF TALEN® GENE EDITING: MULTIPLEXING GENE REPLACEMENT Multiple advantages from combined Knock-Out, Knock-In B2M TRAC CAR @ TRAC 88% double targeted gene Knock-Out 60% double targeted gene insertion TCR and B2M CAR insertion at TCR B2M Knock-Out exposes cells to potential killing NK inhibitor a

  26. Slide 26: With TALEN We Control Off-Target Cleavage

    WITH TALEN® WE CONTROL OFF-TARGET CLEAVAGE Discrimination between ON and OFF-site prevents OFF-site cleavage Utilization of engineered RVDs to discriminate HBB* and HBD** loci preventing unwanted OFF-site cleavage ON-site Engineered RVD HB Natural RVD B Mutation frequency (%) ON-site/OFF-site > 94%

  27. Slide 27: UCART Manufacturing

    UCART MANUFACTURING 1 2 3 4 5 1. Frozen 2. Thawed 3. Lentivector 4. TALEN®- 5. Cell 6. Purification 8. Frozen leukopaks PBMCs transduction mediated gene amplification 7. Fill & Finish UCART editing products More than 5 years of experience in allogeneic CAR T manufacturing Validated gene editing tech

  28. Slide 28: Building 2 State-of-the-Art Plants to Secure Autonomy

    BUILDING 2 STATE-OF-THE-ART PLANTS TO SECURE AUTONOMY SMART – Starting MAterial Realization for CAR-T products • ~14,000 sqft in-house manufacturing in Paris, France • Clinical Starting Materials • Operational "go-live" targeted in 2020 IMPACT – Innovative Manufacturing Plant for Allogeneic Cellular

  29. Slide 29: Anticipated 12-Month Milestones

    ANTICIPATED 12-MONTH MILESTONES 12 months Clinical programs: Manufacturing: Gene editing: UCART19*: Phase 1 in R/R ALL ongoing in 2019 Focusing on refinements to improve agility Explore applications into new areas: and capacity to support future commercial solid tumors and outside oncology UCART123:

  30. Slide 30: Cellectis Highlights

    CELLECTIS HIGHLIGHTS INDUSTRY LEADER IN GENE EDITING & ROBUST PROPRIETARY PIPELINE ALLOGENEIC CAR T (UCART) TECHNOLOGY UCART123 – Phase 1 AML ongoing; dose escalation in First clinical proof-of-concept: UCART19 treated the AML in 2019; wholly- controlled asset first pediatric ALL patient in June 201

  31. Slide 31: The Cellectis Group

    THE CELLECTIS GROUP ~69.1%* ownership NASDAQ: CLLS NASDAQ: CLXT EURONEXT GROWTH: ALCLS $77.9M cash as of June 30, 2019 $401M** cash as of June 30, 2019 Based in Minnesota, USA Expected to fund operations through 2021 Consumer focused Based in Paris, France, New York & Raleigh, USA High value asset P

  32. Slide 32: Thank You

    THANK YOU Cellectis S.A. 8, rue de la Croix Jarry 75013 Paris – France Cellectis, Inc. 430 East 29th Street 10016 New York, NY – USA Cellectis Biologics, Inc. 2500 Sumner Boulevard 27616 Raleigh, NC – USA investor@cellectis.com

Cellectis — Investor Presentation (September 2019) on 6ix